BP180 是头颈部鳞状细胞癌的预后因素。
BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma.
机构信息
Department of Biomarkers for Early Detection of Cancer, National Cancer Center Research Institute, Tokyo, Japan.
Department of Otorhinolaryngology, Juntendo University Faculty of Medicine, Tokyo, Japan.
出版信息
Anticancer Res. 2021 Feb;41(2):1089-1099. doi: 10.21873/anticanres.14867.
BACKGROUND/AIM: Prognosis plays a vital role in head and neck squamous cell carcinoma (HNSCC) patient management and decision-making. This study aimed to identify the role of BP180 as a prognostic factor in HNSCC.
PATIENTS AND METHODS
Protein expression of bullous pemphigoid antigen II (BP180) was verified by immunohistochemistry (IHC) in a tissue microarray study of 202 cases.
RESULTS
IHC analysis revealed that protein expression of BP180 among HNSCC patients differed significantly in the presence and absence of neural invasion, and according to T status in laryngeal and pharyngeal cancer subgroups. Overall survival and multivariate analysis showed that positive BP180-IHC and advanced clinical stage were significant independent positive predictors of mortality in HNSCC patients. In addition, in the oral cancer subgroup, independent positive predictors were positive BP180-IHC, advanced N status and neural invasion. In laryngeal and pharyngeal cancer subgroups, predictors were positive BP180-IHC and advanced clinical stage.
CONCLUSION
BP180 is a prognostic factor in head and neck squamous cell carcinoma.
背景/目的：预后在头颈部鳞状细胞癌（HNSCC）患者的管理和决策中起着至关重要的作用。本研究旨在确定 BP180 作为 HNSCC 预后因素的作用。
患者和方法
通过免疫组织化学（IHC）在 202 例组织微阵列研究中验证大疱性类天疱疮抗原 II（BP180）的蛋白表达。
结果
IHC 分析显示，在存在和不存在神经浸润以及喉癌和咽癌亚组的 T 分期方面，HNSCC 患者的 BP180 蛋白表达存在显著差异。总体生存和多因素分析表明，BP180-IHC 阳性和临床分期较晚是 HNSCC 患者死亡的显著独立阳性预测因子。此外，在口腔癌亚组中，独立的阳性预测因子是 BP180-IHC 阳性、N 分期较晚和神经浸润。在喉癌和咽癌亚组中，预测因子是 BP180-IHC 阳性和临床分期较晚。
结论
BP180 是头颈部鳞状细胞癌的预后因素。
Zotero 插件